GeneDx Holdings
About: GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
Employees: 1,000
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
714% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 7
85% more capital invested
Capital invested by funds: $432M [Q2] → $799M (+$368M) [Q3]
83% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 23
58% more funds holding
Funds holding: 86 [Q2] → 136 (+50) [Q3]
6.73% more ownership
Funds ownership: 63.18% [Q2] → 69.91% (+6.73%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q2] → 6 (+0) [Q3]
38% less call options, than puts
Call options by funds: $4.15M | Put options by funds: $6.74M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$70
10%
downside
Avg. target
$80
3%
upside
High target
$95
23%
upside
3 analyst ratings
1 positive
33%
2 neutral
67%
0 negative
0%
Goldman Sachs Matthew Sykes 64% 1-year accuracy 29 / 45 met price target | 10%downside $70 | Neutral Maintained | 30 Oct 2024 |
Wells Fargo Brandon Couillard 28% 1-year accuracy 5 / 18 met price target | 3%downside $75 | Equal-Weight Maintained | 30 Oct 2024 |
Craig-Hallum Bill Bonello 67% 1-year accuracy 4 / 6 met price target | 23%upside $95 | Buy Maintained | 30 Oct 2024 |
Financial journalist opinion
Based on 4 articles about WGS published over the past 30 days
Neutral
Business Wire
5 days ago
GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference from January 12-16 in San Francisco, CA. Management will participate in a presentation on Wednesday, January 15, 2025, at 4:30 p.m. PT. Live and archived webcasts will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.
Neutral
Business Wire
2 weeks ago
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx today announced Biogen, Praxis Precision Medicines and Stoke Therapeutics as the founding partners to its Patient Access Program for epilepsy.
Positive
Investors Business Daily
3 weeks ago
This Once Ultracheap Biotech Stock Rockets 2,762%, Nears Buy Point After Big Earnings Win
Biotech stock GeneDx soared 50% after earnings on Oct. 29. Shares of the genetic testing company have soared 2,762% year to date.
Neutral
Business Wire
4 weeks ago
GeneDx to Participate in Upcoming Investor Conference
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that company management will participate in the Piper Sandler 36th Annual Healthcare Conference.
Neutral
Business Wire
1 month ago
GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced GeneDx Discover, a first-of-its-kind data visualization tool, which provides biopharmaceutical companies access to deidentified and aggregated genetic data - powered by GeneDx's robust database - to improve all stages of drug development. The new offering is part of GeneDx's ongoing investment to deliver personalized and actionable health insights to.
Neutral
Business Wire
1 month ago
GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Heidi Chen as Chief Legal Officer, effective November 25, 2024. In her role, Heidi will report to Katherine Stueland, CEO and President, and will serve on the executive leadership team. With over 30 years of experience, Heidi will lead all legal, compliance, and policy functions at GeneDx and will provide strategic counsel on corpor.
Positive
The Motley Fool
1 month ago
Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year
Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year
Neutral
Business Wire
1 month ago
New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the results of an extensive study shedding light on the critical issue of racial disparities in access to an accurate genetic diagnosis. The study, a collaboration among GeneDx, The University of Washington, Brotman Baty Institute for Precision Medicine, Geisinger and Seattle Children's Hospital, was conducted on nearly 187,000 samples performed and a.
Neutral
Business Wire
1 month ago
GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American Society of Human Genetics (ASHG) annual meeting. GeneDx data will be presented across six platform presentations and five posters and will unveil findings from key research initiatives constructed on the backbones of its industry leading diverse dataset of more than 700,000 clinical exome and genomes.
Positive
Zacks Investment Research
1 month ago
3 Stocks to Buy for Stellar Earnings Acceleration in November
Stocks like Snap, GeneDx Holdings and Leonardo DRS exhibit solid earnings acceleration.
Charts implemented using Lightweight Charts™